Needham & Company LLC restated their hold rating on shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) in a research report released on Sunday, AnalystRatings.com reports.

Other analysts have also recently issued research reports about the company. HC Wainwright reissued a buy rating and set a $2.00 price objective on shares of Tetraphase Pharmaceuticals in a report on Sunday. Zacks Investment Research raised Tetraphase Pharmaceuticals from a sell rating to a hold rating in a report on Thursday, May 16th. SunTrust Banks dropped their price objective on Tetraphase Pharmaceuticals to $4.00 and set a buy rating on the stock in a report on Friday, May 10th. Finally, ValuEngine raised Tetraphase Pharmaceuticals from a sell rating to a hold rating in a report on Friday, May 10th. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock has an average rating of Buy and a consensus price target of $3.49.

Shares of TTPH opened at $0.29 on Friday. The business’s 50-day moving average is $0.41. The stock has a market cap of $16.92 million, a PE ratio of -0.21 and a beta of 2.28. The company has a debt-to-equity ratio of 0.53, a current ratio of 7.28 and a quick ratio of 7.10. Tetraphase Pharmaceuticals has a 52-week low of $0.28 and a 52-week high of $3.66.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.04). The company had revenue of $1.07 million for the quarter, compared to analysts’ expectations of $2.13 million. Tetraphase Pharmaceuticals had a negative return on equity of 104.50% and a negative net margin of 1,072.60%. As a group, research analysts predict that Tetraphase Pharmaceuticals will post -1.41 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently made changes to their positions in TTPH. JPMorgan Chase & Co. increased its stake in Tetraphase Pharmaceuticals by 803.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 116,428 shares of the biopharmaceutical company’s stock worth $56,000 after acquiring an additional 103,544 shares during the last quarter. Bank of America Corp DE increased its stake in Tetraphase Pharmaceuticals by 6.4% in the 4th quarter. Bank of America Corp DE now owns 142,775 shares of the biopharmaceutical company’s stock worth $161,000 after acquiring an additional 8,567 shares during the last quarter. Two Sigma Advisers LP increased its stake in Tetraphase Pharmaceuticals by 50.2% in the 4th quarter. Two Sigma Advisers LP now owns 221,000 shares of the biopharmaceutical company’s stock worth $250,000 after acquiring an additional 73,900 shares during the last quarter. Edmond DE Rothschild Holding S.A. increased its stake in Tetraphase Pharmaceuticals by 90.9% in the 1st quarter. Edmond DE Rothschild Holding S.A. now owns 210,000 shares of the biopharmaceutical company’s stock worth $281,000 after acquiring an additional 100,000 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in Tetraphase Pharmaceuticals by 4.1% in the 4th quarter. Geode Capital Management LLC now owns 551,837 shares of the biopharmaceutical company’s stock worth $623,000 after acquiring an additional 21,854 shares during the last quarter. Institutional investors and hedge funds own 38.44% of the company’s stock.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc, a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Recommended Story: What Does a Sell-Side Analyst Rating Mean?

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.